An early-phase clinical trial showed that ipatasertib, an Akt inhibitor, combined with paclitaxel improved the progression-free survival of patients with TN breast cancer compared to paclitaxel alone (6.2 vs. 4.9 months, p = 0.037) [91]. The gene discussed is AKT1; the disease is breast cancer.